SARS-COV-2019
APN01 – Our work on a potential drug candidate for COVID-19 treatment
We are developing a potential drug candidate APN01* (alunacedase alfa), based on our proprietary ACE2 platform to address the growing global health threat of COVID-19. APN01 is ideally suited to prevent the infection with SARS-CoV-2, reduce injury to multiple organs and mitigate the deleterious consequences of established viral infection. ACE2, and its role in respiratory...
April 2, 2020
No Comments
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China.
Investigator Initiated Trial (IIT) to start in China, with an international team of experts from China, Austria, and Canada. 24 patients with severe COVID-19 to be treated in a randomized, dual-arm trial with Apeiron’s ACE2 drug product APN01 APN01 was previously proven to be safe and well tolerated in Phase I and Phase II clinical...
February 26, 2020
No Comments
